Tibsovo Market Report 2026

The tibsovo market size has grown strongly in recent years. It will grow from $1.08 billion in 2025 to $1.19 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to limited availability of idh1-targeted drugs, growing prevalence of aml and cholangiocarcinoma, reliance on conventional chemotherapy, low awareness of genetic mutation testing, restricted access to specialized oncology clinics.

The tibsovo market size is expected to see strong growth in the next few years. It will grow to $1.7 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to development of novel oral targeted therapies, increasing genetic testing and personalized medicine adoption, expansion of combination treatment regimens, rising investment in oncology research, growth of hospital and specialty clinic networks. Major trends in the forecast period include rising adoption of targeted therapies for aml and cholangiocarcinoma, increasing use of oral targeted drugs over intravenous administration, expansion of combination therapy approaches, growing awareness of idh1 mutation testing, enhanced focus on personalized cancer treatment.

The increasing prevalence of acute myeloid leukemia is expected to propel the growth of the TIBSOVO market going forward. Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow that disrupts normal blood cell production, weakens immune function, and adversely affects overall health. The prevalence of acute myeloid leukemia is rising mainly due to the growing global aging population, as AML predominantly affects older adults, and increased life expectancy results in a larger population reaching the age group most at risk for this disease. TIBSOVO supports the treatment of acute myeloid leukemia by selectively targeting IDH1-mutated cancer cells, inhibiting abnormal cell proliferation, slowing disease progression, improving therapeutic response, and enhancing survival outcomes by helping restore normal blood cell formation. For instance, in February 2023, according to a report published by the Leukemia Foundation, an Australia-based non-profit organization, between 2022 and 2035, more than 7,000 children, 6,000 young adults, and 108,000 adults aged 25-65 are projected to be diagnosed with blood cancers, primarily including ALL, AML, and non-Hodgkin lymphoma. Therefore, the increasing prevalence of acute myeloid leukemia is driving the growth of the TIBSOVO market.

Major companies operating in the TIBSOVO market are concentrating on securing regulatory approvals to expand the drug’s market presence and reinforce its leadership in treating IDH1-mutated cancers. Regulatory approvals are formal authorizations granted by health authorities that permit a drug to be marketed and prescribed for specific conditions after verifying its safety and efficacy. For example, in October 2023, Servier Laboratoires, a France-based pharmaceutical company, received approval from the European Commission for TIBSOVO (ivosidenib tablets), making it the first and only IDH1-targeted therapy authorized in Europe for two difficult-to-treat cancers. It is approved for use in combination with azacitidine for newly diagnosed AML patients with an IDH1 R132 mutation who are not eligible for standard induction chemotherapy, and as a monotherapy for adults with locally advanced or metastatic cholangiocarcinoma carrying the same mutation following at least one prior systemic therapy. This approval, supported by orphan drug designation, addresses significant unmet medical needs and offers patients improved treatment options and quality of life.

In December 2023, Servier Group, a France-based pharmaceutical company that markets TIBSOVO (ivosidenib tablets) as a targeted therapy for patients with IDH1-mutated cancers, acquired exclusive rights to develop, manufacture, and commercialize TIBSOVO from CStone Pharmaceuticals for $44 million. This acquisition is intended to strengthen Servier Group’s presence in the fast-growing China and Singapore markets by securing exclusive rights to TIBSOVO, expanding its oncology portfolio with a precision therapy for IDH1-mutated cancers, and accelerating patient access to this innovative treatment in these strategic regions. CStone Pharmaceuticals is a China-based biopharmaceutical company focused on oncology drug development.

Major companies operating in the tibsovo market are Servier Laboratoires, Agios Pharmaceuticals.

North America was the largest region in the tibsovo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tibsovo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tibsovo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the tibsovo market by increasing costs of imported raw materials and active pharmaceutical ingredients (apis) required for oral targeted therapies. Segments such as tablets, capsules, and combination therapy products are particularly impacted, with regions like North America and Europe facing supply chain adjustments due to import duties. While tariffs may increase drug prices and production costs, they also encourage domestic manufacturing, innovation in apis, and localization of supply chains, ultimately strengthening regional production capabilities.

The tibsovo market research report is one of a series of new reports that provides tibsovo market statistics, including tibsovo industry global market size, regional shares, competitors with a tibsovo market share, detailed tibsovo market segments, market trends and opportunities, and any further data you may need to thrive in the tibsovo industry. This tibsovo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tibsovo is an oral targeted therapy mainly prescribed for adults with acute myeloid leukemia (AML) or cholangiocarcinoma who carry a specific mutation in the IDH1 gene. It works by inhibiting the mutated IDH1 enzyme, thereby lowering the levels of an abnormal metabolite that drives cancer cell growth. This action helps restore normal cell differentiation and slows disease progression.

The main product types of Tibsovo include tablets, capsules, combination therapy, and injectable forms. Tablets represent the oral solid dosage form of ivosidenib and are designed for convenient once-daily use. These products are administered via oral and intravenous routes and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. They are used in applications such as cancer treatment, acute myeloid leukemia management, chemotherapy, and targeted therapy, serving end users including hospitals, specialty clinics, research institutions, and homecare settings.

The tibsovo market consists of sales of products including oral tablets, extended-release tablets, soft gel capsules, intravenous injection, and subcutaneous injection. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.